Skip to main content

Table 1 Study characteristics

From: Discrepancy between short-term and long-term effects of bone marrow-derived cell therapy in acute myocardial infarction: a systematic review and meta-analysis

Author Year Country Timing of cell injection Cell injection (n) Control (n) Total patient (n) Cell type Cell delivery route Cell preparation No. of injected cells Follow-up (months)
Assmus et al. [9] 2014 Germany After PCI 101 103 204 MNC IC Ficoll gradient 1 × 106 60
Benedek et al. [10] 2014 Romania After PCI 9 9 18 MNC IC Concentration by apheresis 1.66 ± 0.32 × 109 48
Lee et al. [11] 2014 Korea After PCI 30 28 58 MSC IC 1-month culture 7.2 ± 0.90 × 107 6
Robbers et al. [12] 2014 Netherlands After PCI 30 45 75 BM-MNC/PB-MNC IC Lymphoprep™ 296 ± 164 × 106 4
Gao et al. [13] 2013 China After PCI 21 22 43 MSC IC 2-week culture 3.08 ± 0.52 x 106 6, 12, 24
Surder et al. [14] 2013 Switzerland After PCI 65 67 132 MNC IC Density gradient 5 × 107 - 5 × 108 4
Wohrle et al. [15] 2013 Germany After PCI 29 13 42 MNC IC Ficoll gradient 324 × 106 6, 12, 24, 36
Jazi et al. [16] 2012 Iran After PCI 16 16 32 MNC IC Ficoll gradient 24.6 ± 8.4 × 108 6
Kang et al. [17] 2012 Korea After PCI 57 60 117 PB-MNC IC G-CSF/leukapheresis 1.1 ± 0.5 × 109 6, 24, 60
Skalicka et al. [18] 2012 Czech After PCI 17 10 27 MNC IC Gelfusine 26.4 × 108 4, 24
Traverse et al. [19] 2012 USA After PCI 79 41 120 MNC IC Sepax® 150 × 106 6
Colombo et al. [20] 2011 Italy After PCI 5 5 10 CD133+ MNC IC CD133 by CliniMACS® 4.9-135 × 106 12
Hirsch et al. [21] 2011 Netherlands After PCI 69 65 134 MNC IC Lymphoprep™ 296 ± 164 × 106 4
Pena-Duque et al. [22] 2011 Mexico After PCI 4 4 8 MNC IC Sepax® 1 ~ 2 × 106 CD34+ 6
Plewka et al. [23] 2011 Poland After PCI 40 20 60 MNC IC Safe Flow® 1.44 ± 0.49 × 108 24
Quyyumi et al. [24] 2011 USA After PCI 16 15 31 CD34+ MNC IC Isolex 300i® 5 × 106 6, 12
Roncalli et al. [25] 2011 France After PCI 52 49 101 MNC IC Ficoll 98 ± 8.7 × 106 3
Srimahachota et al. [26] 2011 Thailand After PCI 11 12 23 MNC IC Isoprep® 420 ± 221 × 106 6
Turan et al. [27] 2011 Germany After PCI 38 18 56 MNC IC Point of Care system 1 × 106 3, 12
Yerebakan et al. [28] 2011 Germany During CABG 20 20 40 CD133+ MNC IM CD133 by CliniMACS® 6.0 × 106 108
Grajek et al. [29] 2010 Poland After PCI 31 14 45 MNC IC Ficoll gradient 4.1 ± 1.8 × 108 3, 6, 12
Mansour et al. [30] 2010 Canada After PCI 14   14 CD133+ MNC IC CliniMACS® 10 × 106- 4
Piepoli et al. [31] 2010 Italy After PCI 19 19 38 MNC IC Ficoll gradient 418 × 106 3, 6, 12
Traverse et al. [32] 2010 USA After PCI 30 10 40 MNC IC Ficoll gradient 100 × 106 6
Wohrle et al. [33] 2010 Germany After PCI 29 13 42 MNC IC Ficoll gradient 381 ± 130 × 106 6
Cao et al. [34] 2009 USA After PCI 41 45 86 MNC IC Lymphoprep™ 5 ± 1.2 × 107 48
Hare et al. [35] 2009 USA After PCI 39 21 60 MSC (allogeneic) IV 1-month culture 0.5 ~ 5 × 106 6
Nogueira et al. [36] 2009 Brazil After PCI 14 6 20 MNC IC Ficoll gradient 10 × 106 6
Yao et al. [37] 2009 China After PCI 12 12 24 MNC IC Ficoll gradient 1.9 ± 1.3 × 108 6, 12
Huikuri et al. [38] 2008 Finland After PCI 40 40 80 MNC IC Ficoll gradient 4.02 ± 1.96 × 106 6
Meluzin et al. [39] 2008 Czech After PCI 20 20 40 MNC IC Histopaque1077 1-10 × 107 3, 6, 12
Panovsky et al. [40] 2008 Czech After PCI 13 17 30 MNC IC Histopaque1077 1-10 × 108 3
de Lezo et al. [41] 2007 Spain After PCI 10 10 20 MNC IC Ficoll gradient 9 ± 3 × 108 3
Ge et al. [42] 2006 China After PCI 10 10 20 MNC IC Ficoll gradient 4 × 107 6
Janssens et al. [43] 2006 Belgium After PCI 33 34 67 MNC IC Ficoll gradient 172 ± 72 × 106 4
Lunde et al. [44] 2006 Norway After PCI 47 50 97 MNC IC Ficoll gradient 68 × 106 6, 36
Meluzin et al. [45] 2006 Czech After PCI 22 22 44 MNC IC Histopaque1077 1x107 -1 × 108 3
Schachinger et al. [46] 2006 Germany After PCI 101 103 204 MNC IC Ficoll gradient 236 ± 174 × 106 24
Karpov et al. [47] 2005 Russia After PCI 22 22 44 MNC IC Histopaque1077 88.5 ± 49.2 × 106 6
Ruan et al. [48] 2005 China After PCI 9 11 20 MNC IC Not described Not described 6
Chen et al. [49] 2004 China After PCI 34 35 69 MSC IC 10-day culture 2-5 × 106 3, 6
Kang et al. [50] 2004 Korea After PCI 6 7 13 PB-MNC IC G-CSF/leukapheresis 1 × 109 6, 24
Wollert et al. [51] 2004 Germany After PCI 30 30 60 MNC IC 4 % gelatine-polysuccinate 24.6 ± 9.4 × 108 6, 18, 60
  1. Included studies were all randomized clinical trials (RCTs). Plus-minus value indicates mean ± SE
  2. PCI percutaneous coronary intervention, MNC mononuclear cell, IC intracoronary cell infusion, BM-MNC bone marrow-derived mononuclear cell, PB-MNC peripheral blood-derived mononuclear cell, G-CSF granulocyte colony-stimulating factor, CABG coronary artery bypass graft, IM intramyocardial cell injection, IV intravenous cell infusion, MSC mesenchymal stromal cell